Deflazacort - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for deflazacort and what is the scope of patent protection?
Deflazacort
is the generic ingredient in two branded drugs marketed by Tris Pharma Inc, Ptc Therap, Aurobindo Pharma Ltd, and Upsher Smith Labs, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.There are three drug master file entries for deflazacort. Three suppliers are listed for this compound.
Summary for deflazacort
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 4 |
NDAs: | 5 |
Drug Master File Entries: | 3 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 75 |
Clinical Trials: | 23 |
Patent Applications: | 6,857 |
What excipients (inactive ingredients) are in deflazacort? | deflazacort excipients list |
DailyMed Link: | deflazacort at DailyMed |
Recent Clinical Trials for deflazacort
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Parc de Salut Mar | Phase 1 |
FibroGen | Phase 3 |
Catabasis Pharmaceuticals | Phase 1 |
Pharmacology for deflazacort
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for deflazacort
US Patents and Regulatory Information for deflazacort
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aurobindo Pharma Ltd | DEFLAZACORT | deflazacort | TABLET;ORAL | 217123-003 | Feb 9, 2024 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-001 | Feb 9, 2017 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-004 | Feb 9, 2017 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-002 | Feb 9, 2017 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Ptc Therap | EMFLAZA | deflazacort | SUSPENSION;ORAL | 208685-001 | Feb 9, 2017 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Ptc Therap | EMFLAZA | deflazacort | SUSPENSION;ORAL | 208685-001 | Feb 9, 2017 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Deflazacort Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.